GILD Gilead Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GILD

Price (delayed)

$169.32

Market cap

$210.01B

P/E Ratio

N/A

Dividend/share

$3.25

EPS

-$3.1

Enterprise value

$229.81B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 28

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV ...

Highlights
GILD's gross profit is up by 8% YoY and by 2.2% QoQ
GILD's revenue is up by 7% year-on-year
Gilead Sciences's equity has decreased by 39% YoY but it has increased by 10% from the previous quarter
The quick ratio has grown by 27% from the previous quarter but it has contracted by 6% YoY
The company's net income has shrunk by 148% YoY and by 19% QoQ
GILD's EPS has dropped by 148% year-on-year and by 19% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.gilead.com
Peers: AMGN VRTX ABBV ILMN

Key stats

What are the main financial stats of GILD

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
-0.24%
1 week
1.04%
1 month
12.56%
1 year
37.21%
YTD
37.95%
QTD
13.6%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$30.99B
Gross profit
$24.77B
Operating income
-$2.36B
Net income
-$3.86B
Gross margin
79.9%
Net margin
-12.5%
The company's net income has shrunk by 148% YoY and by 19% QoQ
Gilead Sciences's net margin has shrunk by 145% YoY and by 18% QoQ
The operating income has dropped by 123% year-on-year but it has grown by 5% since the previous quarter
The operating margin has plunged by 121% YoY but it has grown by 7% from the previous quarter

Price vs fundamentals

How does GILD's price correlate with its fundamentals

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
GILD P/E details
P/E
N/A
P/B
16.1
P/S
6.79
EV/EBIT
N/A
EV/EBITDA
177.87
EV/Sales
7.42
GILD's EPS has dropped by 148% year-on-year and by 19% since the previous quarter
The stock's price to book (P/B) is 165% more than its 5-year quarterly average of 6.1 and 55% more than its last 4 quarters average of 10.4
Gilead Sciences's equity has decreased by 39% YoY but it has increased by 10% from the previous quarter
GILD's price to sales (P/S) is 70% more than its 5-year quarterly average of 4.0 and 24% more than its last 4 quarters average of 5.5
GILD's revenue is up by 7% year-on-year

Efficiency

How efficient is Gilead Sciences business performance
The company's return on equity has shrunk by 153% YoY and by 33% QoQ
GILD's return on assets has dropped by 151% year-on-year and by 24% since the previous quarter
Gilead Sciences's ROIC has plunged by 113% YoY and by 60% from the previous quarter
GILD's return on sales has dropped by 113% year-on-year and by 58% since the previous quarter

Dividends

What is GILD's dividend history
Dividend details
DPS
$3.25
Dividend yield
1.92%
Payout ratio
N/A
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 34% higher than its total liabilities
The quick ratio has grown by 27% from the previous quarter but it has contracted by 6% YoY
GILD's total assets is down by 12% YoY but it is up by 4.1% QoQ
Gilead Sciences's debt is 101% higher than its equity
The company's debt to equity has surged by 73% YoY but it fell by 9% QoQ
Gilead Sciences's equity has decreased by 39% YoY but it has increased by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.